Danaher CorporationDHREarnings & Financial Report
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments,...
Revenue
$5.9B
Gross Profit
$3.5B
Operating Profit
$760.0M
Net Profit
$555.0M
Gross Margin
59.3%
Operating Margin
12.8%
Net Margin
9.3%
YoY Growth
3.4%
EPS
$0.77
Danaher Corporation Q2 FY2025 Financial Summary
Danaher Corporation reported revenue of $5.9B (up 3.4% YoY) for Q2 FY2025, with a net profit of $555.0M (down 38.8% YoY) (9.3% margin). Cost of goods sold was $2.4B, operating expenses totaled $2.8B.
Key Financial Metrics
| Total Revenue | $5.9B |
|---|---|
| Net Profit | $555.0M |
| Gross Margin | 59.3% |
| Operating Margin | 12.8% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Danaher Corporation Q2 FY2025 revenue of $5.9B breaks down across 6 segments, led by High Growth Markets at $1.7B (28.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| High Growth Markets | $1.7B | 28.6% |
| Revenuefrom Contractwith Customer Measurement Recurring | $1.7B | 28.5% |
| Diagnostics | $1.1B | 17.9% |
| Life Sciences | $762.0M | 12.8% |
| Biotechnology Segment | $612.0M | 10.3% |
| Revenuefrom Contractwith Customer Measurement Nonrecurring | $156.0M | 2.6% |
Danaher Corporation Revenue by Segment — Quarterly Trend
Danaher Corporation revenue by segment across the last 4 reported quarters, showing how each business line (such as High Growth Markets and Revenuefrom Contractwith Customer Measurement Recurring) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| High Growth Markets | — | $2.0B | — | $1.7B |
| Revenuefrom Contractwith Customer Measurement Recurring | — | $1.7B | $1.6B | $1.7B |
| Diagnostics | — | — | $1.2B | $1.1B |
| Life Sciences | — | — | $728.0M | $762.0M |
| Biotechnology Segment | — | $639.0M | $624.0M | $612.0M |
Danaher Corporation Annual Revenue by Year
Danaher Corporation annual revenue history includes year-by-year totals (for example, 2025 revenue was $24.6B).
| Year | Annual Revenue |
|---|---|
| 2025 | $24.6B |
| 2024 | $23.9B |
| 2023 | $23.9B |
Danaher Corporation Quarterly Revenue & Net Profit History
Danaher Corporation results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $6.0B | +3.7% | $1.0B | 17.3% |
| Q4 FY2025 | $6.8B | +4.6% | $1.2B | 17.5% |
| Q3 FY2025 | $6.1B | +4.4% | $908.0M | 15.0% |
| Q2 FY2025 | $5.9B | +3.4% | $555.0M | 9.3% |
| Q1 FY2025 | $5.7B | -0.9% | $954.0M | 16.6% |
| Q4 FY2024 | $6.5B | +2.1% | $1.1B | 16.6% |
| Q3 FY2024 | $5.8B | +3.1% | $818.0M | 14.1% |
| Q2 FY2024 | $5.7B | -2.9% | $907.0M | 15.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.74B | $5.80B | $6.54B | $5.74B | $5.94B | $6.05B | $6.84B | $5.95B |
| YoY Growth | -2.9% | 3.1% | 2.1% | -0.9% | 3.4% | 4.4% | 4.6% | 3.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $78.56B | $80.61B | $77.54B | $79.12B | $81.62B | $79.90B | $83.46B | N/A |
| Liabilities | $28.66B | $29.32B | $28.00B | $28.27B | $29.29B | $28.83B | $30.93B | N/A |
| Equity | $49.90B | $51.30B | $49.54B | $50.85B | $52.33B | $51.07B | $52.53B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.42B | $1.51B | $2.02B | $1.30B | $1.34B | $1.66B | $2.12B | $1.32B |